オリゴヌクレオチド合成市場 – 2030年までの世界予測

Oligonucleotide Synthesis Market - Global Forecast To 2030

オリゴヌクレオチド合成市場 - 製品 [(医薬品(ASO、siRNA)、合成オリゴ(製品(プライマー、プローブ)]、タイプ [(カスタム、プレデザイン)、試薬、機器]、用途 [治療(希少疾患)、研究、診断] - 2030年までの世界予測
Oligonucleotide Synthesis Market by Product ((Drugs (ASO, siRNA), Synthesized Oligos (Product (Primers, Probes)), Type ((Custom, Predesigned), Reagents, Equipment), Application (Therapeutic (Rare Diseases), Research, Diagnostics) - Global Forecast to 2030

商品番号 : SMB-24262

出版社MarketsandMarkets
出版年月2025年6月
ページ数456
図表数645
価格タイプシングルユーザライセンス
価格USD 4,950
種別英文調査報告書

この調査レポートでは、オリゴヌクレオチド合成市場を、製品(オリゴヌクレオチドベースの医薬品、合成オリゴヌクレオチド、試薬と消耗品、機器)、用途(治療用途、研究用途、診断用途)、エンドユーザー(病院、製薬およびバイオテクノロジー企業、診断研究所、CROおよびCMO、学術研究機関)、および地域(北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東、アフリカ)別に分類しています。

本レポートは、オリゴヌクレオチド合成市場の成長に影響を与える主要な要因(促進要因、制約要因、課題、機会など)に関する詳細な情報を網羅しています。主要業界プレーヤーを徹底的に分析し、事業概要、ソリューション、サービス、主要戦略、新製品・新サービスの発売、買収、オリゴヌクレオチド合成市場に関連する最近の動向に関する洞察を提供しています。本レポートは、オリゴヌクレオチド合成市場エコシステムにおける新興企業の競合分析も網羅しています。

The oligonucleotide synthesis market is projected to reach USD 24.7 billion by 2030 from USD 10.5 billion in 2025, at a CAGR of 18.6% during the forecast period. The growth of this market is driven by several factors, such as the increasing demand for synthesized oligonucleotides like primers & probes for several research & diagnostic applications. Rising technological advancements in oligonucleotide synthesis are also expected to contribute to market growth during the forecast period.

オリゴヌクレオチド合成市場は、2025年の105億米ドルから2030年には247億米ドルに達すると予測されており、予測期間中は年平均成長率(CAGR)18.6%で成長すると見込まれています。この市場の成長は、様々な研究・診断用途におけるプライマーやプローブなどの合成オリゴヌクレオチドの需要増加など、複数の要因によって牽引されています。また、オリゴヌクレオチド合成における技術の進歩も、予測期間中の市場成長に寄与すると予想されます。

オリゴヌクレオチド合成市場 - 2030年までの世界予測
oligonucleotide-synthesis-market-Overview

By product, the oligonucleotide-based drugs segment accounted for the largest share of the market in 2024.

By products, the market is segmented into oligonucleotide-based drugs, synthesized oligonucleotides, reagents & consumables, and equipment. In 2024, the oligonucleotide-based drugs segment accounted for the largest share of the market. The large share of this segment can be attributed to the growing acceptance of these treatments and their proven success, especially for rare & hereditary diseases. Medications such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) target disease-causing genes, providing precise and personalized treatments. This growing demand is fueled by advancements in RNA-targeted therapies and delivery systems, the rising prevalence of genetic diseases, and significant investments in research and development of RNA-based treatments.

In 2024, by application, the therapeutic applications segment accounted for the largest share of the market.

The oligonucleotide synthesis market is segmented into therapeutic applications, research applications, and diagnostic applications. In 2024, the therapeutic applications segment accounted for the largest share of the market. The growth of this market is fueled by the use of oligos such as antisense and siRNA for the treatment of neurological & rare diseases, with ongoing research aiming to expand applications into the treatment of CVD and cancer. Advancements in synthesis technology are expected to fuel the demand for efficient & cost-effective therapeutic approaches, with a comprehensive understanding of molecular disease mechanisms ensuring the discovery of innovative therapeutic targets, thereby contributing to market growth in this segment.

オリゴヌクレオチド合成市場 - 2030年までの世界予測 region
oligonucleotide-synthesis-market-Region

In 2024, North America accounted for the largest share of the oligonucleotide synthesis market.

In 2024, North America accounted for the largest market share, a dominance fueled by the strong presence of key industry players and a significant surge in research initiatives dedicated to advancing oligonucleotide-based therapeutics. Additionally, North America’s well-established healthcare infrastructure and favorable reimbursement policies facilitate the widespread adoption of these innovative treatments, consequently driving research applications in the region. The concentration of numerous global entities also significantly contributes to this market leadership.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
  • By Designation: C-level Executives – 30%, Directors- 45%, and Others- 25%
  • By Region: North America -35%, Europe – 25%, the Asia Pacific -15%, Latin America -10%, the Middle East- 10%, and Africa- 5%

Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), LGC Limited (UK), Agilent Technologies, Inc. (US), Kaneka Corporation (Japan), Maravai LifeSciences (US), Azenta US Inc. (US), Twist Bioscience (US), and GenScript (US) are some of the key companies profiled in the report offering products for research & diagnostic applications.

オリゴヌクレオチド合成市場 - 2030年までの世界予測 ecosystem
oligonucleotide-synthesis-market-Ecosystem

Biogen (US). Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), AstraZeneca (UK), Astellas Pharma Inc. (Japan), Jazz Pharmaceuticals Plc (Ireland), Nippon Shinyaku, Co. Ltd. (Japan), Ionis Pharmaceuticals, Inc. (US), and Novartis AG (Switzerland) are some of the key companies profiled in the report offering products for therapeutic applications.

Research Coverage:

This research report categorizes oligonucleotide synthesis market by Product (Oligonucleotide-based drugs, synthesized oligonucleotide, reagents & consumables, and equipment), application (therapeutic applications, research applications, and diagnostic applications), end user (hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, CROs & CMOs, and academic & research institutes), and region (North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa).

The report’s scope covers detailed information regarding the primary factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the oligonucleotide synthesis market. A thorough analysis of the key industry players has been conducted to provide insights into their business overview, solutions, and services; key strategies; new product & service launches, acquisitions, and recent developments associated with the oligonucleotide synthesis market. This report covers the competitive analysis of upcoming startups in the oligonucleotide synthesis market ecosystem.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the oligonucleotide synthesis market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on the key market drivers, restraints, challenges, trends, and opportunities.

The report provides insights on the following :

  • Analysis of key drivers (Increasing use of synthesized oligos in therapeutic and diagnostic applications, technological advancements in oligonucleotide synthesis, growing government investments in life science research & synthetic biology, and growing focus on personalized medicine), restraints (Complexities associated with oligonucleotide-based drugs), opportunities (Increasing pharma R&D investments in emerging economies), and challenges (Lack of standard regulations, challenges in targeted delivery of oligonucleotides) are influencing the growth of the oligonucleotide synthesis market.
  • Product Approvals: Detailed insights on newly approved products of the oligonucleotide synthesis market.
  • Market Development: Comprehensive information about lucrative markets – the report analyses the oligonucleotide synthesis market across varied regions.
  • Market Diversification: Exhaustive information about new products, recent developments, and investments in the oligonucleotide synthesis market.
  • Pipeline Analysis: Comprehensive information about products under clinical trials.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), and Merck KGaA (Germany), among others offering products for research & diagnostic applications. Other companies include Biogen (US), Alnylam Pharmaceuticals, Inc. (US), and Sarepta Therapeutics, Inc. (US), among others, for the therapeutic applications segment.

Table of Contents

1               INTRODUCTION              43

1.1           STUDY OBJECTIVES       43

1.2           MARKET DEFINITION   43

1.3           INCLUSIONS & EXCLUSIONS       44

1.4           MARKET SCOPE                45

1.4.1        YEARS CONSIDERED      46

1.4.2        CURRENCY CONSIDERED            46

1.5           RESEARCH LIMITATIONS             46

1.6           STAKEHOLDERS               47

1.7           SUMMARY OF CHANGES               47

2               RESEARCH METHODOLOGY       48

2.1           RESEARCH DATA              48

2.1.1        SECONDARY DATA          49

2.1.2        PRIMARY DATA 50

2.2           MARKET SIZE ESTIMATION         51

2.2.1        MARKET SIZE ASSESSMENT, SEGMENT LEVEL    55

2.3           MARKET GROWTH FORECAST   56

2.4           OLIGONUCLEOTIDE-BASED DRUGS MARKET VOLUME ESTIMATION     58

2.5           MARKET BREAKDOWN & DATA TRIANGULATION                 59

2.6           STUDY ASSUMPTIONS  60

2.7           RISK ANALYSIS  60

3               EXECUTIVE SUMMARY  61

4               PREMIUM INSIGHTS       64

4.1           OLIGONUCLEOTIDE SYNTHESIS MARKET OVERVIEW                 64

4.2           NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET,

BY APPLICATION & COUNTRY (2024)      65

4.3           OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2025 VS. 2030                65

4.4           OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2024         66

4.5           OLIGONUCLEOTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES            66

5               MARKET OVERVIEW       67

5.1           INTRODUCTION              67

5.2           MARKET DYNAMICS       67

5.2.1        DRIVERS               68

5.2.1.1    Increasing use of synthesized oligos in therapeutic &

diagnostic applications        68

5.2.1.2    Technological advancements              70

5.2.1.3    Growing government investments in life science research &

synthetic biology  71

5.2.1.4    Growing focus on precision/personalized medicine       72

5.2.2        RESTRAINTS      72

5.2.2.1    Complexities associated with therapeutic oligonucleotides                 72

5.2.3        OPPORTUNITIES              73

5.2.3.1    Increasing R&D investments by key players in emerging economies              73

5.2.4        CHALLENGES    74

5.2.4.1    Lack of standard regulations               74

5.2.4.2    Delivery of oligonucleotide drugs to specific targets      74

5.3           INDUSTRY TRENDS         74

5.3.1        GROWING FOCUS ON DEVELOPMENT OF DRUG DELIVERY TECHNOLOGIES FOR OLIGONUCLEOTIDE-BASED DRUGS 74

5.3.2        GROWING FOCUS ON TECHNOLOGY DEVELOPMENT FOR SUSTAINABLE & LARGE-SCALE SYNTHESIS OF OLIGONUCLEOTIDES   75

5.3.3        FOCUS ON ACQUISITIONS TO ENHANCE MARKET POSITION            76

5.3.4        GROWING USE OF ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS FOR TREATMENT OF NEUROLOGICAL & RARE DISEASES             77

5.4           TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES       78

5.5           VALUE CHAIN ANALYSIS               79

5.6           ECOSYSTEM ANALYSIS  82

5.6.1        ROLE IN ECOSYSTEM     83

5.7           TECHNOLOGY ANALYSIS             83

5.7.1        KEY TECHNOLOGIES     84

5.7.1.1    Solid-phase synthesis           84

5.7.1.2    Liquid-phase synthesis        84

5.7.1.3    Enzymatic oligo synthesis   85

5.7.2        COMPLEMENTARY TECHNOLOGIES       85

5.7.2.1    Polymerase chain reaction (PCR)     85

5.7.2.2    Next-generation sequencing               85

5.7.2.3    Microarray analysis               86

5.7.3        ADJACENT TECHNOLOGIES       86

5.7.3.1    CRISPR 86

5.7.3.2    Lipid nanoparticles               86

5.8           PRICING ANALYSIS          87

5.8.1        AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY KEY PLAYERS, 2022−2024            87

5.8.2        AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, 2022−2024                 89

5.8.3        AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE-BASED DRUGS,

BY KEY PLAYERS, 2022−2024        89

5.8.4        AVERAGE SELLING PRICE OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS,

BY REGION, 2024               91

5.8.5        AVERAGE PRICING TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS,

BY KEY PLAYERS, 2024    93

5.8.6        AVERAGE PRICING TREND OF OLIGONUCLEOTIDE-BASED DRUGS,

BY REGION, 2024               94

5.9           PATENT ANALYSIS          94

5.9.1        PATENTS FILED, BY DOCUMENT TYPE, 2014–2024                 94

5.10         PIPELINE ANALYSIS        97

5.11         TRADE ANALYSIS             99

5.11.1      IMPORT DATA (HS CODE 293499)              99

5.11.2      EXPORT DATA (HS CODE 293499)              101

5.12         KEY CONFERENCES & EVENTS, 2025–2026              102

5.13         TARIFF & REGULATORY LANDSCAPE     104

5.13.1      TARIFF DATA (HS CODE 2934.99, 3822.00)               104

5.13.1.1  Trade policy updates affecting oligonucleotide synthesis market, 2022−2025            104

5.13.1.2  Impact of Tariffs on pricing & supply chain     105

5.13.2      REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS             105

5.13.3      REGULATORY FRAMEWORK       108

5.14         PORTER’S FIVE FORCES ANALYSIS           108

5.14.1      DEGREE OF COMPETITION         109

5.14.2      BARGAINING POWER OF SUPPLIERS       109

5.14.3      BARGAINING POWER OF BUYERS             109

5.14.4      THREAT OF SUBSTITUTES          109

5.14.5      THREAT OF NEW ENTRANTS      109

5.15         KEY STAKEHOLDERS & BUYING CRITERIA            110

5.15.1      KEY STAKEHOLDERS IN BUYING PROCESS           110

5.15.2      BUYING CRITERIA FOR END USERS         111

5.16         CASE STUDY ANALYSIS 113

5.16.1      CASE STUDY 1: THERMO FISHER SCIENTIFIC LEVERAGED ITS OLIGONUCLEOTIDE SYNTHESIS EXPERTISE TO DELIVER LARGE-SCALE

DYE-LABELED OLIGONUCLEOTIDES TO ITS CLIENT      113

5.16.2      CASE STUDY 2: BAKER LAB UTILIZING TWIST BIOSCIENCES OLIGO POOLS FOR EVALUATING PROTEIN FOLDING             113

5.16.3      CASE STUDY 3: ENHANCED MOTOR FUNCTION WITH SPINRAZA TREATMENT IN ADOLESCENTS WITH LATE-ONSET SMA       114

5.17         INVESTMENT/FUNDING SCENARIO        114

5.18         IMPACT OF GENERATIVE AI ON OLIGONUCLEOTIDE SYNTHESIS MARKET       116

5.19         TRUMP TARIFF IMPACT OVERVIEW: OLIGONUCLEOTIDE SYNTHESIS MARKET            118

5.19.1      KEY TARIFF RATES          119

5.19.2      PRICE IMPACT ANALYSIS             120

5.19.3      KEY IMPACT ON VARIOUS REGIONS       121

5.19.3.1  US           121

5.19.3.2  Europe   121

5.19.3.3  APAC     122

5.19.3.4  Rest of the World 122

5.19.4      END-USE INDUSTRY IMPACT     122

5.19.4.1  Hospitals                122

5.19.4.2  Pharmaceutical & biotechnology companies    123

5.19.4.3  Diagnostic laboratories        123

5.19.4.4  CROs & CDMOs 123

5.19.4.5  Academic & research institutes          123

6               OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT           124

6.1           INTRODUCTION              125

6.2           OLIGONUCLEOTIDE-BASED DRUGS       125

6.2.1        OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE                 129

6.2.1.1    Antisense oligonucleotide-based drugs             130

6.2.1.1.1 Growing use of antisense oligos in oligonucleotide-based drugs to boost growth     130

6.2.1.2    siRNA oligonucleotide-based drugs  135

6.2.1.2.1 Large pipeline of products to favor market growth         135

6.2.1.3    Other oligonucleotide-based drugs   139

6.3           SYNTHESIZED OLIGONUCLEOTIDES     142

6.3.1        SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT           145

6.3.1.1    Primers  145

6.3.1.1.1 Increasing applications of oligo primers in DNA sequencing and molecular diagnostics to drive growth               145

6.3.1.2    Probes    149

6.3.1.2.1 Advancements in molecular diagnostic technologies such as FISH and qPCR to support market growth 149

6.3.1.3    DNA oligonucleotides         152

6.3.1.3.1 Diverse usage of DNA oligos to support market growth                 152

6.3.1.4    RNA oligonucleotides          155

6.3.1.4.1 Growing diagnostic and therapeutic applications of RNA oligos to propel growth   155

6.3.1.5    Other synthesized oligonucleotides   158

6.3.2        SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE                 161

6.3.2.1    Custom oligonucleotides     161

6.3.2.1.1 Increasing demand for custom oligonucleotides for therapeutic research studies to drive growth         161

6.3.2.2    Predesigned oligonucleotides             165

6.3.2.2.1 Ability of predesigned oligos to save time required in design and optimization to boost adoption           165

6.4           REAGENTS & CONSUMABLES     168

6.4.1        GROWING DEMAND FOR OLIGOS IN SEQUENCING, DRUG DESIGN, AND GENE SYNTHESIS TO DRIVE MARKET GROWTH FOR REAGENTS            168

6.5           EQUIPMENT      171

6.5.1        TECHNOLOGICAL INNOVATIONS IN OLIGONUCLEOTIDE SYNTHESIZERS TO DRIVE GROWTH IN EQUIPMENT MARKET    171

7               OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION   174

7.1           INTRODUCTION              175

7.2           THERAPEUTIC APPLICATIONS  175

7.2.1        THERAPEUTIC APPLICATIONS MARKET, BY DISEASE TYPE     179

7.2.1.1    Neurological disorders         179

7.2.1.1.1 Growing research on oligonucleotide-based drugs for treatment of DMD and SMA to drive market    179

7.2.1.2    Rare diseases         183

7.2.1.2.1 High specificity & efficacy of oligo-based drugs against rare diseases to support growth  183

7.2.1.3    Other diseases      186

7.3           RESEARCH APPLICATIONS          189

7.3.1        PCR        192

7.3.1.1    Increasing use of PCR in molecular biology research to drive market    192

7.3.2        SEQUENCING    195

7.3.2.1    Advancements in sequencing technologies & low cost of DNA sequencing to boost market                 195

7.3.3        OTHER RESEARCH APPLICATIONS          198

7.4           DIAGNOSTIC APPLICATIONS     201

7.4.1        INCREASING DEMAND FOR RAPID & SPECIFIC METHODS FOR DISEASE DETECTION SUPPORT MARKET GROWTH             201

8               OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER                 205

8.1           INTRODUCTION              206

8.2           HOSPITALS         206

8.2.1        INCREASING FDA APPROVALS FOR OLIGONUCLEOTIDE-BASED DRUGS FOR RARE DISEASES TO DRIVE MARKET 206

8.3           PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES                 210

8.3.1        GROWING APPLICATIONS OF OLIGOS IN DRUG DISCOVERY & THERAPEUTICS TO PROPEL MARKET       210

8.4           DIAGNOSTIC LABORATORIES    213

8.4.1        RISING SIGNIFICANCE OF OLIGOS IN MOLECULAR DIAGNOSTICS TO

FUEL MARKET   213

8.5           CONTRACT RESEARCH ORGANIZATIONS (CROS) & CONTRACT MANUFACTURING ORGANIZATIONS (CMOS)                 216

8.5.1        WIDE RANGE OF CUSTOMIZED OLIGO SERVICES TO SUPPORT

MARKET GROWTH          216

8.6           ACADEMIC RESEARCH INSTITUTES        220

8.6.1        GROWING USE OF OLIGOS FOR GENOMIC RESEARCH APPLICATIONS TO PROPEL MARKET      220

9               OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION                 224

9.1           INTRODUCTION              225

9.2           NORTH AMERICA             226

9.2.1        NORTH AMERICA: MACROECONOMIC OUTLOOK                 227

9.2.2        US           231

9.2.2.1    Government initiatives and strategic developments by leading players to drive market        231

9.2.3        CANADA               235

9.2.3.1    Strong research infrastructure and availability of funding to support market growth        235

9.3           EUROPE               239

9.3.1        EUROPE: MACROECONOMIC OUTLOOK               239

9.3.2        GERMANY           244

9.3.2.1    Government & private funding investments towards health research to drive market      244

9.3.3        UK          248

9.3.3.1    Strategic collaborations & partnerships between key market players to fuel market           248

9.3.4        FRANCE                251

9.3.4.1    Favorable government initiatives for genomics research to

boost demand        251

9.3.5        ITALY    255

9.3.5.1    Increasing R&D expenditure for pharma & biotech companies to support market growth        255

9.3.6        SPAIN    258

9.3.6.1    Favorable funding investments for biomedical research to

drive market          258

9.3.7        REST OF EUROPE             261

9.4           ASIA PACIFIC     265

9.4.1        ASIA PACIFIC: MACROECONOMIC OUTLOOK     265

9.4.2        CHINA  269

9.4.2.1    Expansion of leading pharmaceutical & biotechnology companies to drive market      269

9.4.3        JAPAN   273

9.4.3.1    Growing research initiatives & strategic developments to

boost demand        273

9.4.4        INDIA    276

9.4.4.1    Development of bioclusters and improvements in healthcare infrastructure to propel market          276

9.4.5        AUSTRALIA         279

9.4.5.1    Increasing government initiatives and research funding to support market growth        279

9.4.6        SOUTH KOREA  283

9.4.6.1    Growing research activities and strategic expansions in oligonucleotide synthesis to aid market             283

9.4.7        REST OF ASIA PACIFIC   286

9.5           LATIN AMERICA                290

9.5.1        LATIN AMERICA: MACROECONOMIC OUTLOOK                 290

9.5.2        BRAZIL 294

9.5.2.1    Availability of leading oligo-based therapies to support

market growth       294

9.5.3        MEXICO                297

9.5.3.1    Growing adoption of NGS technology to drive market  297

9.5.4        ARGENTINA       300

9.5.4.1    Increasing research collaborations and government support to

boost market          300

9.5.5        REST OF LATIN AMERICA             304

9.6           MIDDLE EAST   307

9.6.1        MIDDLE EAST: MACROECONOMIC OUTLOOK   307

9.6.2        GCC COUNTRIES              311

9.6.2.1    Saudi Arabia (KSA)              314

9.6.2.1.1 Increasing focus on research & government support to propel market    314

9.6.2.2    United Arab Emirates (UAE)             318

9.6.2.2.1 Growing focus on life sciences research to fuel market  318

9.6.2.3    Other GCC countries           321

9.6.3        REST OF MIDDLE EAST 324

9.7           AFRICA 327

9.7.1        IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT

MARKET GROWTH          327

9.7.2        AFRICA: MACROECONOMIC OUTLOOK 327

10            COMPETITIVE LANDSCAPE         331

10.1         INTRODUCTION              331

10.2         KEY PLAYER STRATEGIES/RIGHT TO WIN            331

10.3         REVENUE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS)                336

10.3.1      REVENUE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2022−2024         336

10.3.2      REVENUE ANALYSIS (THERAPEUTIC APPLICATIONS), 2022−2024            337

10.4         MARKET SHARE ANALYSIS           337

10.4.1      MARKET SHARE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2024     338

10.4.2      MARKET SHARE ANALYSIS (THERAPEUTIC APPLICATIONS),2024      339

10.5         COMPANY EVALUATION MATRIX: KEY PLAYERS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2024             340

10.5.1      STARS   340

10.5.2      EMERGING LEADERS     340

10.5.3      PERVASIVE PLAYERS      340

10.5.4      PARTICIPANTS 340

10.6         COMPANY EVALUATION MATRIX: KEY PLAYERS (THERAPEUTIC APPLICATIONS), 2024    341

10.6.1      STARS   342

10.6.2      EMERGING LEADERS     342

10.6.3      PERVASIVE PLAYERS      342

10.6.4      PARTICIPANTS 342

10.6.5      COMPANY FOOTPRINT:                344

10.6.5.1  Company footprint (Research & diagnostic applications)                 344

10.6.5.2  Region footprint (Research & diagnostic applications) 345

10.6.5.3  Product footprint (Research & diagnostic applications)                 346

10.6.5.4  Application footprint (Research & diagnostic applications)                 346

10.6.5.5  Company footprint (Therapeutic applications)               347

10.6.5.6  Region footprint (Therapeutic applications)   347

10.6.5.7  Product footprint (Therapeutic applications) 348

10.6.5.8  Application footprint (Therapeutic applications)           348

10.7         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024        349

10.7.1      PROGRESSIVE COMPANIES         349

10.7.2      RESPONSIVE COMPANIES            349

10.7.3      DYNAMIC COMPANIES  349

10.7.4      STARTING BLOCKS         349

10.7.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023                 351

10.7.5.1  Detailed list of key startups/SMEs    351

10.7.5.2  Competitive benchmarking of startups/SMEs 352

10.8         COMPANY VALUATION & FINANCIAL METRICS 353

10.8.1      FINANCIAL METRICS (RESEARCH & DIAGNOSTIC APPLICATIONS)                353

10.8.2      COMPANY VALUATION (RESEARCH & DIAGNOSTIC APPLICATIONS)                353

10.8.3      FINANCIAL METRICS (THERAPEUTIC APPLICATIONS)                 354

10.8.4      COMPANY VALUATION (THERAPEUTIC APPLICATIONS)                354

10.9         BRAND/PRODUCT COMPARATIVE ANALYSIS     355

10.9.1      BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT

(RESEARCH & DIAGNOSTIC APPLICATIONS)     355

10.9.2      BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT

(THERAPEUTIC APPLICATIONS)               356

10.10       COMPETITIVE SCENARIO             357

10.10.1   PRODUCT APPROVALS 357

11            COMPANY PROFILES      360

11.1         KEY PLAYERS (RESEARCH & DIAGNOSTIC APPLICATIONS)                360

11.1.1      DANAHER CORPORATION           360

11.1.1.1  Business overview 360

11.1.1.2  Products offered   361

11.1.1.3  Recent developments           365

11.1.1.3.1                Deals      365

11.1.1.3.2                Expansions             365

11.1.1.3.3                Other developments             366

11.1.1.4  MnM view              366

11.1.1.4.1                Key strengths        366

11.1.1.4.2                Strategic choices   366

11.1.1.4.3                Weaknesses & competitive threats     366

11.1.2      THERMO FISHER SCIENTIFIC INC.            367

11.1.2.1  Business overview 367

11.1.2.2  Products offered   368

11.1.2.3  Recent developments           371

11.1.2.3.1                Deals      371

11.1.2.4  MnM view              371

11.1.2.4.1                Key strengths        371

11.1.2.4.2                Strategic choices   371

11.1.2.4.3                Weaknesses & competitive threats     371

11.1.3      MERCK KGAA    372

11.1.3.1  Business overview 372

11.1.3.2  Products offered   373

11.1.3.3  Recent developments           376

11.1.3.3.1                Deals      376

11.1.3.3.2                Expansions             376

11.1.3.4  MnM view              377

11.1.3.4.1                Key strengths        377

11.1.3.4.2                Strategic choices   377

11.1.3.4.3                Weaknesses & competitive threats     377

11.1.4      LGC LIMITED    378

11.1.4.1  Business overview 378

11.1.4.2  Products offered   379

11.1.4.3  Recent developments           381

11.1.4.3.1                Deals      381

11.1.4.3.2                Expansions             382

11.1.4.4  MnM view              382

11.1.4.4.1                Key strengths        382

11.1.4.4.2                Strategic choices   382

11.1.4.4.3                Weaknesses & competitive threats     382

11.1.5      EUROFINS SCIENTIFIC  383

11.1.5.1  Business overview 383

11.1.5.2  Products offered   384

11.1.5.3  Recent developments           385

11.1.5.3.1                Deals      385

11.1.5.3.2                Expansions             386

11.1.5.4  MnM view              386

11.1.5.4.1                Key strengths        386

11.1.5.4.2                Strategic choices   386

11.1.5.4.3                Weaknesses & competitive threats     386

11.1.6      AGILENT TECHNOLOGIES, INC.                387

11.1.6.1  Business overview 387

11.1.6.2  Products offered   388

11.1.6.3  Recent developments           389

11.1.6.3.1                Deals      389

11.1.6.3.2                Expansions             390

11.1.7      KANEKA CORPORATION               391

11.1.7.1  Business overview 391

11.1.7.2  Products offered   392

11.1.7.3  Recent developments           394

11.1.7.3.1                Expansions             394

11.1.8      MARAVAI LIFESCIENCES               395

11.1.8.1  Business overview 395

11.1.8.2  Products offered   396

11.1.8.3  Recent developments           399

11.1.8.3.1                Deals      399

11.1.8.3.2                Expansions             399

11.1.9      AZENTA US INC.               400

11.1.9.1  Business overview 400

11.1.9.2  Products offered   401

11.1.10   TWIST BIOSCIENCE        403

11.1.10.1                 Business overview 403

11.1.10.2                 Products offered   404

11.1.10.3                 Recent developments           405

11.1.10.3.1             Deals      405

11.1.11   GENSCRIPT        406

11.1.11.1                 Business overview 406

11.1.11.2                 Products offered   407

11.1.11.3                 Recent developments           409

11.1.11.3.1             Deals      409

11.1.11.3.2             Expansions             409

11.2         KEY PLAYERS (THERAPEUTIC APPLICATIONS)  410

11.2.1      BIOGEN                410

11.2.1.1  Business overview 410

11.2.1.2  Products offered   411

11.2.1.3  Recent developments           412

11.2.1.3.1                Product approvals 412

11.2.1.3.2                Deals      412

11.2.1.3.3                Expansions             413

11.2.1.4  MnM view              413

11.2.1.4.1                Key strengths        413

11.2.1.4.2                Strategic choices   413

11.2.1.4.3                Weaknesses & competitive threats     413

11.2.2      ALNYLAM PHARMACEUTICALS, INC.      414

11.2.2.1  Business overview 414

11.2.2.2  Products offered   415

11.2.2.3  Recent developments           416

11.2.2.3.1                Product approvals 416

11.2.2.3.2                Deals      417

11.2.2.4  MnM view              417

11.2.2.4.1                Key strengths        417

11.2.2.4.2                Strategic choices   417

11.2.2.4.3                Weaknesses & competitive threats     417

11.2.3      SAREPTA THERAPEUTICS, INC. 418

11.2.3.1  Business overview 418

11.2.3.2  Products offered   419

11.2.3.3  Recent developments           420

11.2.3.3.1                Product approvals 420

11.2.3.3.2                Expansions             420

11.2.3.4  MnM view              420

11.2.3.4.1                Key strengths        420

11.2.3.4.2                Strategic choices   420

11.2.3.4.3                Weaknesses & competitive threats     420

11.2.4      ASTRAZENECA  421

11.2.4.1  Business overview 421

11.2.4.2  Products offered   422

11.2.4.3  Recent developments           423

11.2.4.3.1                Deals      423

11.2.4.3.2                Product Approvals                423

11.2.4.4  MnM view              423

11.2.4.4.1                Key strengths        423

11.2.4.4.2                Strategic choices   423

11.2.4.4.3                Weaknesses & competitive threats     423

11.2.5      ASTELLAS PHARMA INC.               424

11.2.5.1  Business overview 424

11.2.5.2  Products offered   425

11.2.5.3  Recent developments           426

11.2.5.3.1                Deals      426

11.2.5.3.2                Product approvals 426

11.2.5.4  MnM view              426

11.2.5.4.1                Key strengths        426

11.2.5.4.2                Strategic choices   426

11.2.5.4.3                Weaknesses & competitive threats     426

11.2.6      JAZZ PHARMACEUTICALS PLC   427

11.2.6.1  Business overview 427

11.2.6.2  Products offered   428

11.2.7      NIPPON SHINYAKU, CO. LTD.    429

11.2.7.1  Business overview 429

11.2.7.2  Products offered   430

11.2.7.3  Recent developments           431

11.2.7.3.1                Deals      431

11.2.8      IONIS PHARMACEUTICALS, INC.               432

11.2.8.1  Business overview 432

11.2.8.2  Products offered   433

11.2.8.3  Recent developments           434

11.2.8.3.1                Product Approvals                434

11.2.8.3.2                Deals      434

11.2.9      NOVARTIS AG   436

11.2.9.1  Business overview 436

11.2.9.2  Products offered   437

11.2.9.3  Recent developments           438

11.2.9.3.1                Product Approvals                438

11.2.9.3.2                Deals      438

11.3         OTHER PLAYERS              439

11.3.1      OLIGOMAKER APS (PART OF TAG COPENHAGEN A/S)                 439

11.3.2      BIOLEGIO B.V.  440

11.3.3      BIOLYTIC LAB PERFORMANCE, INC.       441

11.3.4      BIOCOMMA LIMITED     442

11.3.5      REVVITY (SUBSIDIARY OF HORIZON DISCOVERY LTD.)                 443

11.3.6      BIO-SYNTHESIS, INC.     444

11.3.7      CREATIVE BIOGENE       445

11.3.8      REPROCELL INC. (THROUGH SUBSIDIARY BIOSERVE)                 447

12            APPENDIX           448

12.1         DISCUSSION GUIDE        448

12.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                452

12.3         CUSTOMIZATION OPTIONS        454

12.4         RELATED REPORTS         454

12.5         AUTHOR DETAILS           455

LIST OF TABLES

TABLE 1                OLIGONUCLEOTIDE SYNTHESIS MARKET: IMPACT ANALYSIS           68

TABLE 2                FDA-APPROVED OLIGONUCLEOTIDE-BASED THERAPIES (2016−2025)                69

TABLE 3                LIST OF ACQUISITIONS IN OLIGONUCLEOTIDE SYNTHESIS MARKET       76

TABLE 4                APPROVED ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS  78

TABLE 5                AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY KEY PLAYERS, 2022−2024            87

TABLE 6                AVERAGE SELLING PRICE TREND FOR OLIGONUCLEOTIDE-BASED DRUGS,

BY KEY PLAYERS, 2022-2024          89

TABLE 7                AVERAGE SELLING PRICE OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS,

BY REGION, 2024               91

TABLE 8                AVERAGE SELLING PRICE FOR OLIGONUCLEOTIDE-BASED DRUGS,

BY REGION, 2024               94

TABLE 9                INDICATIVE LIST OF PATENTS IN OLIGONUCLEOTIDE SYNTHESIS MARKET            96

TABLE 10              IMPORT VALUE OF HS CODE 293499-COMPLIANT PRODUCTS FOR

TOP 20 COUNTRIES, 2020–2024 (USD THOUSAND)            99

TABLE 11              IMPORT VOLUME FOR HS CODE 293499-COMPLIANT PRODUCTS FOR

TOP 20 COUNTRIES, 2020–2024 (TONS)  100

TABLE 12              EXPORT VALUE OF HS CODE 293499-COMPLIANT PRODUCTS FOR

TOP 20 COUNTRIES, 2020–2024 (USD THOUSAND)            101

TABLE 13              EXPORT VOLUME FOR HS CODE 9027-COMPLIANT PRODUCTS FOR

TOP 20 COUNTRIES, 2020–2024 (TONS)S                 102

TABLE 14              OLIGONUCLEOTIDE SYNTHESIS MARKET: LIST OF CONFERENCES & EVENTS     102

TABLE 15              NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  105

TABLE 16              EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  106

TABLE 17              ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  106

TABLE 18              LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  107

TABLE 19              MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  107

TABLE 20              OLIGONUCLEOTIDE SYNTHESIS MARKET: PORTER’S FIVE FORCES ANALYSIS           108

TABLE 21              KEY COMPANIES IMPLEMENTING AI      117

TABLE 22              US ADJUSTED RECIPROCAL TARIFF RATES                 119

TABLE 23              KEY PRODUCT-RELATED TARIFF: MISCELLANEOUS CHEMICAL PRODUCTS, PHARMACEUTICAL PRODUCTS, ORGANIC CHEMICALS.        120

TABLE 24              CRITICAL COMPONENTS EXPOSED TO TARIFF CHANGES            121

TABLE 25              OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            125

TABLE 26              OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION,

2023–2030 (USD MILLION)            126

TABLE 27              NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 126

TABLE 28              EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            127

TABLE 29              ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            127

TABLE 30              LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            128

TABLE 31              MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            128

TABLE 32              GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 128

TABLE 33              OLIGONUCLEOTIDE-BASED DRUGS MARKET VOLUME, BY PRODUCT,

2023–2030 (NUMBER OF VIALS)  129

TABLE 34              OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)         130

TABLE 35              APPROVED ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS  131

TABLE 36              ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION,

2023–2030 (USD MILLION)            132

TABLE 37              NORTH AMERICA: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               132

TABLE 38              EUROPE: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            133

TABLE 39              ASIA PACIFIC: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               133

TABLE 40              LATIN AMERICA: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               134

TABLE 41              MIDDLE EAST: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               134

TABLE 42              GCC COUNTRIES: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               134

TABLE 43              APPROVED SIRNA OLIGONUCLEOTIDE-BASED DRUGS 135

TABLE 44              SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION,

2023–2030 (USD MILLION)            136

TABLE 45              NORTH AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               136

TABLE 46              EUROPE: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            137

TABLE 47              ASIA PACIFIC: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            137

TABLE 48              LATIN AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            138

TABLE 49              MIDDLE EAST: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            138

TABLE 50              GCC COUNTRIES: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            138

TABLE 51              APPROVED OTHER OLIGONUCLEOTIDE-BASED DRUGS 139

TABLE 52              OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION,

2023–2030 (USD MILLION)            140

TABLE 53              NORTH AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               140

TABLE 54              EUROPE: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            140

TABLE 55              ASIA PACIFIC: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            141

TABLE 56              LATIN AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            141

TABLE 57              MIDDLE EAST: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            141

TABLE 58              GCC COUNTRIES: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               142

TABLE 59              SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION,

2023–2030 (USD MILLION)            143

TABLE 60              NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            143

TABLE 61              EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            143

TABLE 62              ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            144

TABLE 63              LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            144

TABLE 64              MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            144

TABLE 65              GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            145

TABLE 66              SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            145

TABLE 67              OLIGONUCLEOTIDE PRIMERS MARKET, BY REGION, 2023–2030 (USD MILLION)          146

TABLE 68              NORTH AMERICA: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            146

TABLE 69              EUROPE: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            147

TABLE 70              ASIA PACIFIC: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            147

TABLE 71              LATIN AMERICA: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            148

TABLE 72              MIDDLE EAST: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            148

TABLE 73              GCC COUNTRIES: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            148

TABLE 74              OLIGONUCLEOTIDE PROBES MARKET, BY REGION, 2023–2030 (USD MILLION)          150

TABLE 75              NORTH AMERICA: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            150

TABLE 76             EUROPE: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            150

TABLE 77              ASIA PACIFIC: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            151

TABLE 78              LATIN AMERICA: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            151

TABLE 79              MIDDLE EAST: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            151

TABLE 80              GCC COUNTRIES: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            152

TABLE 81              DNA OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION)          153

TABLE 82              NORTH AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            153

TABLE 83              EUROPE: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            153

TABLE 84              ASIA PACIFIC: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            154

TABLE 85              LATIN AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            154

TABLE 86              MIDDLE EAST: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            154

TABLE 87              GCC COUNTRIES: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            155

TABLE 88             RNA OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION)            156

TABLE 89              NORTH AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            156

TABLE 90              EUROPE: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            156

TABLE 91              ASIA PACIFIC: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            157

TABLE 92              LATIN AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            157

TABLE 93              MIDDLE EAST: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            157

TABLE 94              GCC COUNTRIES: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            158

TABLE 95              OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION,

2023–2030 (USD MILLION)            159

TABLE 96              NORTH AMERICA: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               159

TABLE 97              EUROPE: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            159

TABLE 98              ASIA PACIFIC: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            160

TABLE 99              LATIN AMERICA: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               160

TABLE 100            MIDDLE EAST: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            160

TABLE 101            GCC COUNTRIES: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               161

TABLE 102            SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)         161

TABLE 103            CUSTOM OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION)          162

TABLE 104            NORTH AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            162

TABLE 105            EUROPE: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            163

TABLE 106            ASIA PACIFIC: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            163

TABLE 107            LATIN AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            164

TABLE 108            MIDDLE EAST: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            164

TABLE 109            GCC COUNTRIES: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            164

TABLE 110            PREDESIGNED OLIGONUCLEOTIDES MARKET, BY REGION,

2023–2030 (USD MILLION)            165

TABLE 111            NORTH AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            165

TABLE 112            EUROPE: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            166

TABLE 113            ASIA PACIFIC: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            166

TABLE 114            LATIN AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            167

TABLE 115            MIDDLE EAST: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            167

TABLE 116            GCC COUNTRIES: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            167

TABLE 117            OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET,

BY REGION, 2023–2030 (USD MILLION)   168

TABLE 118            NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     169

TABLE 119            EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 169

TABLE 120            ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 169

TABLE 121            LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     170

TABLE 122            MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 170

TABLE 123            GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     170

TABLE 124            OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY REGION,

2023–2030 (USD MILLION)            171

TABLE 125            NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               172

TABLE 126            EUROPE: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 172

TABLE 127            ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 172

TABLE 128            LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               173

TABLE 129            MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 173

TABLE 130            GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               173

TABLE 131            OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            175

TABLE 132            OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,

BY REGION, 2023–2030 (USD MILLION)   176

TABLE 133            NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)     177

TABLE 134            EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)            177

TABLE 135            ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)            177

TABLE 136            LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)     178

TABLE 137            MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)       178

TABLE 138            GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)     178

TABLE 139            OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,

BY DISEASE TYPE, 2023–2030 (USD MILLION)       179

TABLE 140            OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS,

BY REGION, 2023–2030 (USD MILLION)   180

TABLE 141            NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)     180

TABLE 142            EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)       181

TABLE 143            ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)       181

TABLE 144            LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)     182

TABLE 145            MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)       182

TABLE 146            GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)     182

TABLE 147            OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY REGION,

2023–2030 (USD MILLION)            183

TABLE 148            NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)       184

TABLE 149            EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)               184

TABLE 150            ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)               184

TABLE 151            LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)               185

TABLE 152            MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES,

BY REGION, 2023–2030 (USD MILLION)   185

TABLE 153            GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)       185

TABLE 154            OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY REGION, 2023–2030 (USD MILLION)                 186

TABLE 155            NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)       187

TABLE 156            EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)               187

TABLE 157            ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)               187

TABLE 158            LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)       188

TABLE 159            MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES,

BY REGION, 2023–2030 (USD MILLION)   188

TABLE 160            GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)       188

TABLE 161            OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)                 189

TABLE 162            OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,

BY REGION, 2023–2030 (USD MILLION)   189

TABLE 163            NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)     190

TABLE 164            EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)       190

TABLE 165            ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)       190

TABLE 166            LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)     191

TABLE 167            MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 191

TABLE 168            GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)     191

TABLE 169            OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY REGION,

2023–2030 (USD MILLION)            192

TABLE 170            NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION)            193

TABLE 171            EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY,

2023–2030 (USD MILLION)            193

TABLE 172            ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION)                 193

TABLE 173            LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION)            194

TABLE 174            MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY REGION, 2023–2030 (USD MILLION)                 194

TABLE 175            GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION)            194

TABLE 176            OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY REGION,

2023–2030 (USD MILLION)            196

TABLE 177            NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING,

BY COUNTRY, 2023–2030 (USD MILLION)               196

TABLE 178            EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING,

BY COUNTRY, 2023–2030 (USD MILLION)               196

TABLE 179            ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING,

BY COUNTRY, 2023–2030 (USD MILLION)               197

TABLE 180            LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING,

BY COUNTRY, 2023–2030 (USD MILLION)               197

TABLE 181            MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING,

BY REGION, 2023–2030 (USD MILLION)   197

TABLE 182            GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING,

BY COUNTRY, 2023–2030 (USD MILLION)               198

TABLE 183            OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS,

BY REGION, 2023–2030 (USD MILLION)   199

TABLE 184            NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)     199

TABLE 185            EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)            199

TABLE 186            ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)            200

TABLE 187            LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)     200

TABLE 188            MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)            200

TABLE 189            GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)     201

TABLE 190            OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS,

BY REGION, 2023–2030 (USD MILLION)   202

TABLE 191            NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)     202

TABLE 192            EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)       202

TABLE 193            ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)       203

TABLE 194            LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)     203

TABLE 195            MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)       203

TABLE 196            GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)     204

TABLE 197            OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,

2023–2030 (USD MILLION)            206

TABLE 198            OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY REGION,

2023–2030 (USD MILLION)            207

TABLE 199            NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS,

BY COUNTRY, 2023–2030 (USD MILLION)               207

TABLE 200            EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)            208

TABLE 201            ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS,

BY COUNTRY, 2023–2030 (USD MILLION)               208

TABLE 202            LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS,

BY COUNTRY, 2023–2030 (USD MILLION)               209

TABLE 203            MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS,

BY REGION, 2023–2030 (USD MILLION)   209

TABLE 204            GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS,

BY COUNTRY, 2023–2030 (USD MILLION)               209

TABLE 205            OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)          211

TABLE 206            NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)            211

TABLE 207            EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)   211

TABLE 208            ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)   212

TABLE 209            LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)            212

TABLE 210            MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)        212

TABLE 211            GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)            213

TABLE 212            OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES,

BY REGION, 2023–2030 (USD MILLION)   214

TABLE 213            NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)     214

TABLE 214            EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)            214

TABLE 215            ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)            215

TABLE 216            LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)     215

TABLE 217            MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION)       215

TABLE 218            GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)     216

TABLE 219            OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY REGION,

2023–2030 (USD MILLION)            217

TABLE 220            NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS,

BY COUNTRY, 2023–2030 (USD MILLION)               218

TABLE 221            EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS,

BY COUNTRY, 2023–2030 (USD MILLION)               218

TABLE 222            ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS,

BY COUNTRY, 2023–2030 (USD MILLION)               218

TABLE 223            LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS,

BY COUNTRY, 2023–2030 (USD MILLION)               219

TABLE 224            MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS,

BY REGION, 2023–2030 (USD MILLION)   219

TABLE 225            GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS,

BY COUNTRY, 2023–2030 (USD MILLION)               219

TABLE 226            OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)            221

TABLE 227            NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)               221

TABLE 228            EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)            221

TABLE 229            ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)            222

TABLE 230            LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)               222

TABLE 231            MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)            222

TABLE 232            GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)               223

TABLE 233            OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2023–2030 (USD MILLION)          225

TABLE 234            NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            227

TABLE 235            NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            228

TABLE 236            NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,

2023–2030 (USD MILLION)            228

TABLE 237            NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)            229

TABLE 238            NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,

2023–2030 (USD MILLION)            229

TABLE 239            NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            229

TABLE 240            NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)             230

TABLE 241            NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)            230

TABLE 242            NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,

2023–2030 (USD MILLION)            231

TABLE 243            US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            232

TABLE 244            US: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,

2023–2030 (USD MILLION)            233

TABLE 245            US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            233

TABLE 246            US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,

2023–2030 (USD MILLION)            233

TABLE 247            US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            234

TABLE 248            US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,

BY DISEASE TYPE, 2023–2030 (USD MILLION)       234

TABLE 249            US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         234

TABLE 250            US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,

2023–2030 (USD MILLION)            235

TABLE 251            CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            236

TABLE 252            CANADA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,

2023–2030 (USD MILLION)            236

TABLE 253            CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            237

TABLE 254            CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,

2023–2030 (USD MILLION)            237

TABLE 255            CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            237

TABLE 256            CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)            238

TABLE 257            CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 238

TABLE 258            CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,

2023–2030 (USD MILLION)            238

TABLE 259            EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            241

TABLE 260            EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            241

TABLE 261            EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,

2023–2030 (USD MILLION)            242

TABLE 262            EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            242

TABLE 263            EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,

2023–2030 (USD MILLION)            242

TABLE 264            EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            243

TABLE 265            EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)            243

TABLE 266            EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 243

TABLE 267            EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,

2023–2030 (USD MILLION)            244

TABLE 268            GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            245

TABLE 269            GERMANY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,

2023–2030 (USD MILLION)            245

TABLE 270            GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            246

TABLE 271            GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,

2023–2030 (USD MILLION)            246

TABLE 272            GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            246

TABLE 273            GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)            247

TABLE 274            GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 247

TABLE 275            GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,

2023–2030 (USD MILLION)            247

TABLE 276            UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            249

TABLE 277            UK: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,

2023–2030 (USD MILLION)            249

TABLE 278            UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            249

TABLE 279            UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,

2023–2030 (USD MILLION)            250

TABLE 280            UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            250

TABLE 281            UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,

BY DISEASE TYPE, 2023–2030 (USD MILLION)       250

TABLE 282            UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         251

TABLE 283            UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,

2023–2030 (USD MILLION)            251

TABLE 284            FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            252

TABLE 285            FRANCE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,

2023–2030 (USD MILLION)            252

TABLE 286            FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            253

TABLE 287            FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,

2023–2030 (USD MILLION)            253

TABLE 288            FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            253

TABLE 289            FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)            254

TABLE 290            FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 254

TABLE 291            FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,

2023–2030 (USD MILLION)            254

TABLE 292            ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            255

TABLE 293            ITALY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,

2023–2030 (USD MILLION)            256

TABLE 294            ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            256

TABLE 295            ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,

2023–2030 (USD MILLION)            256

TABLE 296            ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            257

TABLE 297            ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)            257

TABLE 298            ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         257

TABLE 299            ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,

2023–2030 (USD MILLION)            258

TABLE 300            SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            259

TABLE 301            SPAIN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,

2023–2030 (USD MILLION)            259

TABLE 302            SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            259

TABLE 303            SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,

2023–2030 (USD MILLION)            260

TABLE 304            SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            260

TABLE 305            SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)            260

TABLE 306            SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         261

TABLE 307            SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,

2023–2030 (USD MILLION)            261

TABLE 308            REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            262

TABLE 309            REST OF EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,

2023–2030 (USD MILLION)            262

TABLE 310            REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)            263

TABLE 311            REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,

2023–2030 (USD MILLION)            263

TABLE 312            REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            263

TABLE 313            REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)             264

TABLE 314            REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)            264

TABLE 315            REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,

2023–2030 (USD MILLION)            264

TABLE 316            ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            266

TABLE 317            ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            266

TABLE 318            ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,

2023–2030 (USD MILLION)            267

TABLE 319            ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            267

TABLE 320            ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,

2023–2030 (USD MILLION)            267

TABLE 321            ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            268

TABLE 322            ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)            268

TABLE 323            ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 268

TABLE 324            ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,

2023–2030 (USD MILLION)            269

TABLE 325            CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            270

TABLE 326            CHINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,

2023–2030 (USD MILLION)            270

TABLE 327            CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            271

TABLE 328            CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,

2023–2030 (USD MILLION)            271

TABLE 329            CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            271

TABLE 330            CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)            272

TABLE 331            CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         272

TABLE 332            CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,

2023–2030 (USD MILLION)            272

TABLE 333            JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            273

TABLE 334            JAPAN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,

2023–2030 (USD MILLION)            274

TABLE 335            JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            274

TABLE 336            JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,

2023–2030 (USD MILLION)            274

TABLE 337            JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            275

TABLE 338            JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)            275

TABLE 339            JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         275

TABLE 340            JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,

2023–2030 (USD MILLION)            276

TABLE 341            INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            277

TABLE 342            INDIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,

2023–2030 (USD MILLION)            277

TABLE 343            INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            277

TABLE 344            INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,

2023–2030 (USD MILLION)            278

TABLE 345            INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            278

TABLE 346            INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)            278

TABLE 347            INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,

BY TYPE, 2023–2030 (USD MILLION)         279

TABLE 348            INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,

2023–2030 (USD MILLION)            279

TABLE 349            AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            280

TABLE 350            AUSTRALIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,

2023–2030 (USD MILLION)            280

TABLE 351            AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            281

TABLE 352            AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,

2023–2030 (USD MILLION)            281

TABLE 353            AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            281

TABLE 354            AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)            282

TABLE 355            AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 282

TABLE 356            AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,

2023–2030 (USD MILLION)            282

TABLE 357            SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            283

TABLE 358            SOUTH KOREA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,

2023–2030 (USD MILLION)            284

TABLE 359            SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            284

TABLE 360            SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,

2023–2030 (USD MILLION)            284

TABLE 361            SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            285

TABLE 362            SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)             285

TABLE 363            SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)            285

TABLE 364            SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,

2023–2030 (USD MILLION)            286

TABLE 365            REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)                 287

TABLE 366            REST OF ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)                 287

TABLE 367            REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)            288

TABLE 368            REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)            288

TABLE 369            REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            288

TABLE 370            REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)             289

TABLE 371            REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)            289

TABLE 372            REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)                 289

TABLE 373            LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            290

TABLE 374            LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            291

TABLE 375            LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,

2023–2030 (USD MILLION)            291

TABLE 376            LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)            292

TABLE 377            LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,

2023–2030 (USD MILLION)            292

TABLE 378            LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            292

TABLE 379            LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)             293

TABLE 380            LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)            293

TABLE 381            LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,

2023–2030 (USD MILLION)            293

TABLE 382            BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            294

TABLE 383            BRAZIL: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,

2023–2030 (USD MILLION)            294

TABLE 384            BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            295

TABLE 385            BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,

2023–2030 (USD MILLION)            295

TABLE 386            BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            295

TABLE 387            BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)            296

TABLE 388            BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 296

TABLE 389            BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,

2023–2030 (USD MILLION)            296

TABLE 390            MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            297

TABLE 391            MEXICO: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,

2023–2030 (USD MILLION)            298

TABLE 392            MEXICO: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            298

TABLE 393            MEXICO: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,

2023–2030 (USD MILLION)            298

TABLE 394            MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            299

TABLE 395            MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)            299

TABLE 396            MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 299

TABLE 397            MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,

2023–2030 (USD MILLION)            300

TABLE 398            ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            301

TABLE 399            ARGENTINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,

2023–2030 (USD MILLION)            301

TABLE 400            ARGENTINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            302

TABLE 401            ARGENTINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,

2023–2030 (USD MILLION)            302

TABLE 402            ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            302

TABLE 403            ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)            303

TABLE 404            ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 303

TABLE 405            ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,

2023–2030 (USD MILLION)            303

TABLE 406            REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)                 304

TABLE 407            REST OF LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)                 304

TABLE 408            REST OF LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET,

BY PRODUCT, 2023–2030 (USD MILLION)               305

TABLE 409            REST OF LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)            305

TABLE 410            REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       305

TABLE 411            REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)             306

TABLE 412            REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)            306

TABLE 413            REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)                 306

TABLE 414            MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION,

2023–2030 (USD MILLION)            307

TABLE 415            MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            308

TABLE 416            MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,

2023–2030 (USD MILLION)            308

TABLE 417            MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            309

TABLE 418            MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,

2023–2030 (USD MILLION)            309

TABLE 419            MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            309

TABLE 420            MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)            310

TABLE 421            MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 310

TABLE 422            MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,

2023–2030 (USD MILLION)            310

TABLE 423            GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            311

TABLE 424            GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            311

TABLE 425            GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,

2023–2030 (USD MILLION)            312

TABLE 426            GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)            312

TABLE 427            GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,

2023–2030 (USD MILLION)            312

TABLE 428            GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            313

TABLE 429            GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)             313

TABLE 430            GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)            313

TABLE 431            GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,

2023–2030 (USD MILLION)            314

TABLE 432            SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            315

TABLE 433            SAUDI ARABIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,

2023–2030 (USD MILLION)            315

TABLE 434            SAUDI ARABIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            316

TABLE 435            SAUDI ARABIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,

2023–2030 (USD MILLION)            316

TABLE 436            SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            316

TABLE 437            SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)            317

TABLE 438            SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 317

TABLE 439            SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,

2023–2030 (USD MILLION)            317

TABLE 440            UNITED ARAB EMIRATES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)                 318

TABLE 441            UNITED ARAB EMIRATES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)                 319

TABLE 442            UNITED ARAB EMIRATES: SYNTHESIZED OLIGONUCLEOTIDES MARKET,

BY PRODUCT, 2023–2030 (USD MILLION)               319

TABLE 443            UNITED ARAB EMIRATES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)            319

TABLE 444            UNITED ARAB EMIRATES: OLIGONUCLEOTIDE SYNTHESIS MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       320

TABLE 445            UNITED ARAB EMIRATES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)             320

TABLE 446            UNITED ARAB EMIRATES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)            320

TABLE 447            UNITED ARAB EMIRATES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)                 321

TABLE 448            OTHER GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)                 321

TABLE 449            OTHER GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)                 322

TABLE 450            OTHER GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET,

BY PRODUCT, 2023–2030 (USD MILLION)               322

TABLE 451            OTHER GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)            322

TABLE 452            OTHER GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       323

TABLE 453            OTHER GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)             323

TABLE 454            OTHER GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)            323

TABLE 455            OTHER GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)                 324

TABLE 456            REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION)                 324

TABLE 457            REST OF MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION)                 325

TABLE 458            REST OF MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET,

BY PRODUCT, 2023–2030 (USD MILLION)               325

TABLE 459            REST OF MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION)            325

TABLE 460            REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)            326

TABLE 461            REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)             326

TABLE 462            REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)            326

TABLE 463            REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION)                 327

TABLE 464            AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            328

TABLE 465            AFRICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,

2023–2030 (USD MILLION)            328

TABLE 466            AFRICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            329

TABLE 467            AFRICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,

2023–2030 (USD MILLION)            329

TABLE 468            AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            329

TABLE 469            AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION)            330

TABLE 470            AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 330

TABLE 471            AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,

2023–2030 (USD MILLION)            330

TABLE 472            STRATEGIES ADOPTED BY KEY PLAYERS IN OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH & DIAGNOSTIC APPLICATIONS), 2022–2025               332

TABLE 473            STRATEGIES ADOPTED BY KEY PLAYERS IN OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS), 2022–2025           334

TABLE 474            OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH & DIAGNOSTIC APPLICATIONS): DEGREE OF COMPETITION 338

TABLE 475            OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS):

DEGREE OF COMPETITION         339

TABLE 476            OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH & DIAGNOSTIC APPLICATIONS): REGIONAL FOOTPRINT       345

TABLE 477            OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH & DIAGNOSTIC APPLICATIONS): PRODUCT FOOTPRINT       346

TABLE 478            OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH & DIAGNOSTIC APPLICATIONS): APPLICATION FOOTPRINT       346

TABLE 479            OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS):

REGION FOOTPRINT     347

TABLE 480            OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS):

PRODUCT FOOTPRINT 348

TABLE 481            OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): APPLICATION FOOTPRINT                 348

TABLE 482            DETAILED LIST OF KEY STARTUPS/SMES                 351

TABLE 483            COMPETITIVE BENCHMARKING OF STARTUPS/SMES              352

TABLE 484            OLIGONUCLEOTIDE SYNTHESIS MARKET: PRODUCT APPROVALS,

JANUARY 2022–MAY 2025               357

TABLE 485            OLIGONUCLEOTIDE SYNTHESIS MARKET: DEALS, JANUARY 2022-MAY 2025                358

TABLE 486            OLIGONUCLEOTIDE SYNTHESIS MARKET: EXPANSIONS, JANUARY 2022-MAY 2025   359

TABLE 487            DANAHER CORPORATION: COMPANY OVERVIEW          360

TABLE 488            DANAHER CORPORATION: PRODUCTS OFFERED             361

TABLE 489            DANAHER CORPORATION: DEALS, JANUARY 2021−MAY 2025 365

TABLE 490            DANAHER CORPORATION: EXPANSIONS, JANUARY 2021−MAY 2025             365

TABLE 491            DANAHER CORPORATION: OTHER DEVELOPMENTS              366

TABLE 492            THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW          367

TABLE 493            THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED             368

TABLE 494            THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021−MAY 2025             371

TABLE 495            MERCK KGAA: COMPANY OVERVIEW     372

TABLE 496            MERCK KGAA: PRODUCTS OFFERED      373

TABLE 497            MERCK KGAA: DEALS, JANUARY 2021−MAY 2025                 376

TABLE 498            MERCK KGAA: EXPANSIONS, JANUARY 2021−MAY 2025 376

TABLE 499            LGC LIMITED: COMPANY OVERVIEW     378

TABLE 500            LGC LIMITED: PRODUCTS OFFERED      379

TABLE 501            LGC LIMITED: DEALS, JANUARY 2021−MAY 2025                 381

TABLE 502            LGC LIMITED: EXPANSIONS, JANUARY 2021−MAY 2025 382

TABLE 503            EUROFINS SCIENTIFIC: COMPANY OVERVIEW                 383

TABLE 504            EUROFINS SCIENTIFIC: PRODUCTS OFFERED                 384

TABLE 505            EUROFINS SCIENTIFIC: DEALS, JANUARY 2021−MAY 2025 385

TABLE 506            EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2021−MAY 2025 386

TABLE 507            AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW          387

TABLE 508            AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED             388

TABLE 509            AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2021−MAY 2025             389

TABLE 510            AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2021−MAY 2025             390

TABLE 511            KANEKA CORPORATION: COMPANY OVERVIEW                 391

TABLE 512            KANEKA CORPORATION: PRODUCTS OFFERED                 392

TABLE 513            KANEKA CORPORATION: EXPANSIONS, JANUARY 2021−MAY 2025             394

TABLE 514            MARAVAI LIFESCIENCES: COMPANY OVERVIEW                 395

TABLE 515            MARAVAI LIFESCIENCES: PRODUCTS OFFERED                 396

TABLE 516            MARAVAI LIFESCIENCES: DEALS, JANUARY 2021−MAY 2025 399

TABLE 517            MARAVAI LIFESCIENCES: EXPANSIONS, JANUARY 2021−MAY 2025             399

TABLE 518            AZENTA US INC.: COMPANY OVERVIEW                 400

TABLE 519            AZENTA US INC.: PRODUCTS OFFERED 401

TABLE 520            TWIST BIOSCIENCE: COMPANY OVERVIEW                 403

TABLE 521            TWIST BIOSCIENCE: PRODUCTS OFFERED                 404

TABLE 522            TWIST BIOSCIENCE: DEALS, JANUARY 2021−MAY 2025 405

TABLE 523            GENSCRIPT: COMPANY OVERVIEW         406

TABLE 524            GENSCRIPT: PRODUCTS OFFERED          407

TABLE 525            GENSCRIPT: DEALS, JANUARY 2021−MAY 2025                 409

TABLE 526            GENSCRIPT: EXPANSIONS, JANUARY 2021−MAY 2025        409

TABLE 527            BIOGEN: COMPANY OVERVIEW 410

TABLE 528            BIOGEN: PRODUCTS OFFERED 411

TABLE 529            BIOGEN: PRODUCT APPROVALS, JANUARY 2021−MAY 2025 412

TABLE 530            BIOGEN: DEALS, JANUARY 2021−MAY 2025                 412

TABLE 531            BIOGEN: EXPANSIONS, JANUARY 2021−MAY 2025        413

TABLE 532            ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW          414

TABLE 533            ALNYLAM PHARMACEUTICALS, INC.: PRODUCTS OFFERED    415

TABLE 534            ALNYLAM PHARMACEUTICALS INC.: PRODUCT APPROVALS,

JANUARY 2021−MAY 2025             416

TABLE 535            ALNYLAM PHARMACEUTICALS INC.: DEALS, JANUARY 2021−MAY 2025             417

TABLE 536            SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW          418

TABLE 537            SAREPTA THERAPEUTICS, INC.: PRODUCTS OFFERED             419

TABLE 538            SAREPTA THERAPEUTICS: PRODUCT APPROVALS, JANUARY 2021−MAY 2025  420

TABLE 539            SAREPTA THERAPEUTICS: EXPANSIONS, JANUARY 2021−MAY 2025             420

TABLE 540            ASTRAZENECA: COMPANY OVERVIEW  421

TABLE 541            ASTRAZENECA: PRODUCTS OFFERED   422

TABLE 542            ASTRAZENECA: DEALS, JANUARY 2021−MAY 2025        423

TABLE 543            ASTRAZENECA: PRODUCT APPROVALS, JANUARY 2021−MAY 2025             423

TABLE 544            ASTELLAS PHARMA INC.: COMPANY OVERVIEW                 424

TABLE 545            ASTELLAS PHARMA INC.: PRODUCTS OFFERED                 425

TABLE 546            ASTELLAS PHARMA INC.: DEALS, JANUARY 2021−MAY 2025 426

TABLE 547            ASTELLAS PHARMA INC.: PRODUCT APPROVALS, JANUARY 2021−MAY 2025  426

TABLE 548            JAZZ PHARMACEUTICALS PLC: COMPANY OVERVIEW          427

TABLE 549            JAZZ PHARMACEUTICALS PLC: PRODUCTS OFFERED             428

TABLE 550            NIPPON SHINYAKU, CO. LTD.: COMPANY OVERVIEW          429

TABLE 551            NIPPON SHINYAKU, CO. LTD.: PRODUCTS OFFERED             430

TABLE 552            NIPPON SHINYAKU, CO. LTD.: DEALS, JANUARY 2021−MAY 2025 431

TABLE 553            IONIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW          432

TABLE 554            IONIS PHARMACEUTICALS, INC.: PRODUCTS OFFERED             433

TABLE 555            IONIS PHARMACEUTICALS, INC.: PRODUCT APPROVALS, JANUARY 2021−MAY 2025  434

TABLE 556            IONIS PHARMACEUTICALS, INC.: DEALS, JANUARY 2021−MAY 2025             434

TABLE 557            NOVARTIS AG: COMPANY OVERVIEW    436

TABLE 558            NOVARTIS AG: PRODUCTS OFFERED     437

TABLE 559            NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2021−MAY 2025             438

TABLE 560            NOVARTIS AG: DEALS, JANUARY 2021−MAY 2025                 438

TABLE 561            OLIGOMAKER APS: COMPANY OVERVIEW                 439

TABLE 562            BIOLEGIO B.V.: COMPANY OVERVIEW   440

TABLE 563            BIOLYTIC LAB PERFORMANCE, INC.: COMPANY OVERVIEW          441

TABLE 564            BIOCOMMA LIMITED: COMPANY OVERVIEW                 442

TABLE 565            REVVITY: COMPANY OVERVIEW               443

TABLE 566            BIO-SYNTHESIS, INC.: COMPANY OVERVIEW                 444

TABLE 567            CREATIVE BIOGENE: COMPANY OVERVIEW                 445

TABLE 568            REPROCELL INC.: COMPANY OVERVIEW                 447

LIST OF FIGURES

FIGURE 1              OLIGONUCLEOTIDE SYNTHESIS MARKET SEGMENTATION              45

FIGURE 2              RESEARCH DESIGN         48

FIGURE 3              BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS  50

FIGURE 4              MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2024  51

FIGURE 5              MARKET SIZE ESTIMATION: APPROACH 1A (REVENUE SHARE ANALYSIS FOR RESEARCH & DIAGNOSTIC APPLICATIONS), 2024     52

FIGURE 6              MARKET SIZE ESTIMATION: APPROACH 1B (REVENUE SHARE ANALYSIS FOR THERAPEUTIC APPLICATIONS), 2024     52

FIGURE 7              ILLUSTRATIVE EXAMPLE OF DANAHER CORPORATION (RESEARCH & DIAGNOSTIC APPLICATIONS): REVENUE SHARE ANALYSIS, 2024               53

FIGURE 8              ILLUSTRATIVE EXAMPLE OF BIOGEN INC. (THERAPEUTIC APPLICATIONS):

REVENUE SHARE ANALYSIS, 2024               53

FIGURE 9              MARKET VALIDATION FROM PRIMARY EXPERTS              55

FIGURE 10            MARKET SIZE ESTIMATION: TOP-DOWN APPROACH         55

FIGURE 11            CAGR PROJECTIONS: OLIGONUCLEOTIDE SYNTHESIS MARKET, 2025–2030  57

FIGURE 12            CAGR PROJECTIONS: OLIGONUCLEOTIDE-BASED DRUGS MARKET

(THERAPEUTIC APPLICATIONS), 2025–2030          57

FIGURE 13            GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES,

AND CHALLENGES IN OLIGONUCLEOTIDE SYNTHESIS MARKET                 58

FIGURE 14            DATA TRIANGULATION METHODOLOGY                 59

FIGURE 15            OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,

2025 VS. 2030 (USD MILLION)      61

FIGURE 16            OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,

2025 VS. 2030 (USD MILLION)      62

FIGURE 17            OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,

2024−2029 (USD MILLION)          62

FIGURE 18            GEOGRAPHIC SNAPSHOT OF OLIGONUCLEOTIDE SYNTHESIS MARKET            63

FIGURE 19            RISING DEMAND FOR SYNTHESIZED OLIGOS FOR DRUG DISCOVERY & DEVELOPMENT TO DRIVE MARKET                 64

FIGURE 20            THERAPEUTIC APPLICATIONS SEGMENT ACCOUNTED FOR MARKET

SHARE IN US IN 2O24      65

FIGURE 21            OLIGONUCLEOTIDE-BASED DRUGS SEGMENT TO DOMINATE MARKET IN 2030                65

FIGURE 22            THERAPEUTIC APPLICATIONS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2024       66

FIGURE 23            NORTH AMERICA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD  66

FIGURE 24            OLIGONUCLEOTIDE SYNTHESIS MARKET: DRIVERS, RESTRAINTS,

OPPORTUNITIES, AND CHALLENGES     67

FIGURE 25            REVENUE SHIFT AND NEW REVENUE POCKETS FOR

OLIGONUCLEOTIDE MANUFACTURERS                78

FIGURE 26            VALUE CHAIN ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS)—MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE         80

FIGURE 27            VALUE CHAIN ANALYSIS (THERAPEUTIC APPLICATIONS)—MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE            81

FIGURE 28            ECOSYSTEM ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET       82

FIGURE 29            AVERAGE PRICING TREND OF OLIGONUCLEOTIDE

SYNTHESIS PRODUCTS, 2022−2024          89

FIGURE 30            AVERAGE PRICING TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS,

BY KEY PLAYERS, 2024    93

FIGURE 31            TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR OLIGONUCLEOTIDE SYNTHESIS PATENTS (JANUARY 2014–DECEMBER 2024) 95

FIGURE 32            OLIGONUCLEOTIDE DRUGS PIPELINE, BY DISEASE               97

FIGURE 33            OLIGONUCLEOTIDE DRUGS PIPELINE, BY PHASE  98

FIGURE 34            OLIGONUCLEOTIDE DRUGS PIPELINE, BY REGION                98

FIGURE 35            INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES    110

FIGURE 36            STAKEHOLDERS INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS: HOSPITALS                 110

FIGURE 37            BUYING CRITERIA OF END USERS FOR SYNTHESIZED

OLIGONUCLEOTIDE PRODUCTS              111

FIGURE 38            BUYING CRITERIA OF HOSPITALS FOR SYNTHESIZED

OLIGONUCLEOTIDE PRODUCTS              112

FIGURE 39            NIH FUNDING FOR OLIGONUCLEOTIDE SYNTHESIS PROJECTS, 2014–2024               115

FIGURE 40            AI USE CASES     117

FIGURE 41            NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT               226

FIGURE 42            EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT       240

FIGURE 43            OLIGONUCLEOTIDE SYNTHESIS MARKET: REVENUE ANALYSIS

(RESEARCH & DIAGNOSTIC APPLICATIONS), 2022–2024  336

FIGURE 44            OLIGONUCLEOTIDE SYNTHESIS MARKET: REVENUE ANALYSIS

(THERAPEUTIC APPLICATIONS), 2022–2024          337

FIGURE 45            OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS), BY KEY PLAYER, 2024      338

FIGURE 46            MARKET SHARE ANALYSIS (THERAPEUTIC APPLICATIONS), BY KEY PLAYER, 2024   339

FIGURE 47            OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2024     341

FIGURE 48            OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX FOR

KEY PLAYERS (THERAPEUTIC APPLICATIONS), 2024        343

FIGURE 49            OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH & DIAGNOSTIC APPLICATIONS): COMPANY FOOTPRINT       344

FIGURE 50            OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS):

COMPANY FOOTPRINT 347

FIGURE 51            OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX

FOR STARTUPS/SMES, 2024          350

FIGURE 52            EV/EBITDA OF KEY VENDORS (RESEARCH & DIAGNOSTIC APPLICATIONS)   353

FIGURE 53            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF

KEY VENDORS (RESEARCH & DIAGNOSTIC APPLICATIONS)                 353

FIGURE 54            EV/EBITDA OF KEY VENDORS (THERAPEUTIC APPLICATIONS)                354

FIGURE 55            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF

KEY VENDORS (THERAPEUTIC APPLICATIONS)                 354

FIGURE 56            BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT

(RESEARCH & DIAGNOSTIC APPLICATIONS)       355

FIGURE 57            BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT

(THERAPEUTIC APPLICATIONS)               356

FIGURE 58            DANAHER CORPORATION: COMPANY SNAPSHOT (2024)             361

FIGURE 59            THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)             368

FIGURE 60            MERCK KGAA: COMPANY SNAPSHOT (2024)                 373

FIGURE 61            LGC LIMITED: COMPANY SNAPSHOT (2024)                 379

FIGURE 62            EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024)    384

FIGURE 63            AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024)             388

FIGURE 64            KANEKA CORPORATION: COMPANY SNAPSHOT (2024)    392

FIGURE 65            MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2024)    396

FIGURE 66            AZENTA US INC.: COMPANY SNAPSHOT (2024)                 401

FIGURE 67            TWIST BIOSCIENCE: COMPANY SNAPSHOT (2024)    404

FIGURE 68            GENSCRIPT: COMPANY SNAPSHOT (2024)                 407

FIGURE 69            BIOGEN: COMPANY SNAPSHOT (2024)   411

FIGURE 70            ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2024)             415

FIGURE 71            SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2024)             419

FIGURE 72            ASTRAZENECA: COMPANY SNAPSHOT (2024)                 422

FIGURE 73            ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2024)    425

FIGURE 74            JAZZ PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2024)             428

FIGURE 75            NIPPON SHINYAKU, CO. LTD.: COMPANY SNAPSHOT (2024)             430

FIGURE 76            IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2024)             432

FIGURE 77            NOVARTIS AG: COMPANY SNAPSHOT (2024)                 437